| Identifier | Protein names | Gene names | Cross reference refseq | Length | Species |
| U5ZBU8 | Cytochrome b; | CYTB; | NULL | 380 | human |
| Q2VF45 | Coagulation factor VIII; Fragment; | F8; | NULL | 155 | human |
| Q400I9 | Arylamine N-acetyltranserase 1; EC 2.3.1.5; Arylamine N-acetyltransferase; EC 2.3.1.5; Fragment; | NAT1; | NULL | 42 | human |
| L7P4C4 | NADH-ubiquinone oxidoreductase chain 5; EC 1.6.5.3; | ND5; | NULL | 603 | human |
| B5BU81 | YKT6 v-SNARE protein; | YKT6; | NULL | 198 | human |
| A1DVN4 | NADH-ubiquinone oxidoreductase chain 5; EC 1.6.5.3; | ND5; | NULL | 603 | human |
| E5KLM1 | Mitochondrial dynamin-like 120 kDa protein; | NULL | NULL | 997 | human |
| Q4GB09 | Cytochrome b; | cytb; CYTB; | NULL | 380 | human |
| I3V9S3 | Dipeptidyl peptidase 1 isoform a preproprotein; EC 3.4.14.1; Fragment; | CTSC; | NULL | 48 | human |
| M0R2G3 | KxDL motif-containing protein 1; | KXD1; | NULL | 128 | human |
| M0R164 | Inactive serine/threonine-protein kinase VRK3; | VRK3; | NULL | 72 | human |
| G9LI64 | NADH-ubiquinone oxidoreductase chain 2; EC 1.6.5.3; | ND2; | NULL | 347 | human |
| K7EQA6 | Breast carcinoma-amplified sequence 3; | BCAS3; | NULL | 53 | human |
| A7XT95 | Cytochrome b; | cytb; CYTB; | NULL | 380 | human |
| B7Z982 | Pleiotropic regulator 1; cDNA FLJ57451, highly similar to Pleiotropic regulator 1; | PLRG1; | NULL | 131 | human |
| M0QX59 | Zinc finger protein 415; | ZNF415; | NULL | 73 | human |
| F2Z3G2 | 85/88 kDa calcium-independent phospholipase A2; | PLA2G6; | NULL | 99 | human |
| Q14X83 | Cytochrome c oxidase subunit 1; EC 1.9.3.1; Fragment; | NULL | NULL | 133 | human |
| Q2I9M3 | SP110; SP110 protein; Fragment; | SP110; | NULL | 49 | human |
| G9LDT9 | NADH-ubiquinone oxidoreductase chain 5; EC 1.6.5.3; | ND5; | NULL | 603 | human |
UrgentMab™: Thinking is cheap. Test your ideas, fast and furious. |
 |
|
Custom monoclonal antibody in one month. As low as $200-300 per antigen. |
|
A product of Absolution |
|
SEAL™: Today's out-of-reach protein targets made accessible. |
|
|
Same budget, 5-10 times more antibodying SEAL your protein. Successes too. |
|
A product of Absolution |
|
PETAL™: Fast and high throughput antibody discover platform. |
 |
|
Deliver customized antibody in two weeks at price of category antibody Proteome-scale antibody discovery for any organism or proteome Biomarker discovery for biological processes or human diseases |
|
A product of Absolution |
|
AbFocus™: Target all the modification sites of your protein, affordably. |
|
|
Test them with a panel of AbFocus antibodies It is so affordable that you can focus on testing, not guessing |
|
A product of Absolution |
Mabome™: Catch the antibody gold rush.? Lead the next omics revolution. |
|
|
First-ever antibody proteomics technology. High quality monoclonal antibodies for your favorite proteome. As low as $19/monoclonal antibody |
|
A product of Absolution |
AbTarget™: Performing antibody for your proteome.? Guaranteed |
|
|
Fast, efficient monoclonal antibody development for proteins in a proteome Pay for successful antibodies only |
|
A product of Absolution |
AbProfile™: Discover an array of unbiased differences.? Proteome-scale |
|
|
50,000 monoclonal antibodies on an array.100 times more content. Differential profiling thousands of cell surface receptorsand plasma proteins |
|
A product of Absolution |
|
SMAL™:?All big things have a SMAL beginning. |
|
|
High success rate for mAb generation Deliver a panel of high affinity mAbs Flexible and optional fee structure for minimizing risks |
|
A product of Absolution |
AbX™: X=anything.? Find your antibody within |
|
|
currently 7species.?200,000 mAbs.70,000 proteins 3 new organisms are being AbXed/day Pre-made anti-peptide mAbs against all proteins in nature. |
|
A product of AbStore |
AbStop™: The last stop of antibody development. The most successful stop. |
|
|
Pre-designed antibody packages against high value targets The most aggressive and comprehensive protein targeting Best for diagnostics and therapeutic antibody development |
|
A product of AbStore |